Inhaled Nitric Oxide Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Inhaled Nitric Oxide Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

The global inhaled nitric oxide market size reached US$ 806.1 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 1,274.4 Million by 2027, exhibiting a growth rate (CAGR) of 8.1% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Inhaled nitric oxide (iNO) refers to a selective pulmonary vasodilator supervised by skilled physicians at tertiary neonatal intensive care units (NICUs). It assists in regulating vascular muscle tone and treating hypoxemic respiratory failure among newly born infants by improving ventilation-perfusion mismatch and reducing elevated pulmonary vascular resistance and hypertension. It also aids in improving oxygenation and decreasing the need for extracorporeal membrane oxygenation (ECMO). At present, there is a rise in the use of iNO therapy as a rescue agent for acute respiratory distress syndrome (ARDS) patients.

Inhaled Nitric Oxide Market Trends:
The increasing prevalence of respiratory and other subsequent diseases in newborns, such as persistent pulmonary hypertension and neonatal hypoxic respiratory failure (HRF), represents one of the primary factors significantly contributing to the market growth. Additionally, the rising geriatric population, which is relatively more prone to hypertension, atherosclerosis, peripheral artery disease, heart failure, and thrombosis, is supporting the growth of the market. Furthermore, iNO is gaining immense traction worldwide for treating chronic obstructive pulmonary diseases (COPD), asthma, and ARDS. Moreover, the outbreak of the highly contagious coronavirus disease (COVID-19) and an alarmingly increasing number of individuals getting infected on a global level are favorably influencing the market. Furthermore, iNO therapy is being used against coronavirus stains as it assists in improving ventilation/perfusion in patients with severe pneumonia. The market is also driven by the ongoing research and development (R&D) activities in the healthcare industry around the world to improve the overall patient experience.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global inhaled nitric oxide market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on application.

Breakup by Application:

Neonatal Respiratory Treatment
Chronic Obstructive Pulmonary Disease (COPD)
Acute Respiratory Distress Syndrome (ARDS)
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Air Liquide S.A, Bellerophon Therapeutics, Beyond Air Inc., Linde plc, Mallinckrodt plc, Merck KGaA, Novoteris LLC, Nu-Med Plus and VERO Biotech LLC.

Key Questions Answered in This Report:
How has the global inhaled nitric oxide market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global inhaled nitric oxide market?
What are the key regional markets?
What is the breakup of the market based on the application?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global inhaled nitric oxide market and who are the key players?
What is the degree of competition in the industry?